EX-10.39A 2 ex10-39a.htm
EXIBIT 10.39(a)

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND (II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.

AMENDMENT NO. 1
TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT

This Amendment No. 1 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of April 4, 2019 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of Texas System (“System”).

RECITALS

A.
Cell Source and MD Anderson entered into a Veto Cell Production and Clinical Trial Program Agreement dated February 19, 2019 (the “Agreement”).

B.
Cell Source and MD Anderson wish to amend the terms of the Agreement as set forth below.

NOW, THEREFORE, it is hereby agreed as follows:

1.
Exhibit B of the Agreement shall be revised in its entirety with the attached Amended Exhibit B.

2.
Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as provided therein.

IN WITNESS WHEREOF, Cell Source and MD Anderson have entered into this Amendment effective as of the date first set forth above.

CELL SOURCE
  
THE UNIVERSITY OF TEXAS
  

  M.D. ANDERSON CANCER CENTER  
       
       
By /s/ Itamar Shimrat
  
By /s/ Nyma Shah
  
Itamar Shimrat
  
Name:  Nyma Shah
  
Chief Executive Officer
  
Title:  Director, Research Funding Programs
  
       
Date: April 4, 2019
  
Date: April 19, 2019
  
       
       
   
Read & Understood:
  
       
       
   
/s/ Richard Champlin
  
   
Dr. Richard Champlin
  
   
Principal Investigator

  
EXIBIT 10.39(a)

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND (II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.

Amended Exhibit B

PAYMENT PLAN



Payment Terms

Payments shall be made by Electronic Funds Transfer via the Automated Clearing House (ACH), which is MD Anderson’s preferred method to receive payments, or by wire or check.  With each payment, Sponsor shall provide the appropriate MD Anderson Research Contracts Tracking Number (RCTS # 56497 and MD Anderson’s invoice number (GRNXXXXXX) if applicable.  To minimize any delays in receiving and applying payments, Sponsor will provide the following information via email transmission to GC_Payments@mdanderson.org at the time payment is issued to MD Anderson:

·
the name of the bank submitting the payment,
·
RCTS number : [     ]
·
amount of the payment,
·
MD Anderson Principal Investigator Richard Champlin MD
·
Sponsor contact name or email regarding Payments
·
Sponsor Protocol number 2018-0221

Electronic Payments (ACH and Wire) 
Bank Name:                       JP Morgan Chase Bank, N.A
Bank Address:                  910 Travis
                                            Houston, Texas 77002
Account Name:                Univ of Texas MD Anderson Cancer Center
Account Number:            [          ]
Domestic Banks:              ABA Routing Number: 111000614 (ACH) 021000021 (Wire)
Internal Swift:                   CHASUS33 (international)

Checks should be mailed to:

The University of Texas
MD Anderson Cancer Center
Attn: Grants and Contracts RCTS # 56497
P.O. BOX 4266
Houston, Texas 77210-4266

If Sponsor issues a payment to MD Anderson that combines payments for multiple studies, Sponsor will provide a detail listing including MD Anderson Principal Investigator and the amount of payment for each study via email transmission to GC_Payments@mdanderson.org upon issuing payment to MD Anderson.

EXIBIT 10.39(a)

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND (II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.


EXHIBIT B- BUDGET
 
Funding Agency:
 
 
Cell Source Limited
  
Principal Investigator:
Champlin, Richard
  
Title:
Role of Veto Cells in Haploidentical Transplantation for Myeloma
  
Project Dates:
TBD
  
Protocol(s)
2018-0221
3% increase
Total Patients
[_____]
  
 
*
 
  

                                   
Year 1
    
Year 2
        
Personnel
    
Base Salary
    
Cal Mths.
    
Effort
    
Salary
    
Fringe
    
Total
    
Total
    
Grand Total
  
 
[          
]
     [          
]
     [          
]
    
[[          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
  [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
  [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
  [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
  [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
     [          
]
                                                                     
Salary Total
                                            
$
 [           
]
  
$
 [          
]
     [          
]
Equipment
                                            
$
--
    
$
--
      
--
  
Consultant Costs
                                            
$
               $    
                                                                     
Total
                                            
$
--
    
$
--
    
$
--
  
                                                                     
Supplies
                                                                  
                                                                     
Travel
                                                                  
                                                                     
Total
                                                                  

Patient Care Costs
CTRC Admin Fee

Other Direct Costs

  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]***
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
  [          
]
  
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
       
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
Total
    
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
                                         
Direct Costs
                                     
Indirect Costs [ ]%
    
$
    
[________]
  
$
    
[_________]
  
$
    
[_________]
Total Costs
          
$1,103,978.68
        
$811,249.33
        
$1,915,228.01
   
***[       ].